![](https://www.coherentbio.com/wp-content/uploads/2024/07/44-800x600.jpg)
Author By adminPosted on
On June 24, 2024, local time, the U.S. Food and Drug Administration (FDA) notified the approval of Orphan Drug Designation (ODD) f...
![](https://www.coherentbio.com/wp-content/uploads/2024/07/55-800x600.jpg)
ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention
Author By adminPosted on
The American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held from May 31 to June 4 in Chicago, USA. At this year...
![](https://www.coherentbio.com/wp-content/uploads/2024/07/22-800x600.jpg)
Author By adminPosted on
Recently, Coherent Biopharma disclosed the latest preclinical research progress of CBP-8008, at the 2024 American Association...
![](https://www.coherentbio.com/wp-content/uploads/2024/03/1-1-800x600.jpg)
Author By adminPosted on
From March 12 to 15, 2024, the 14th World Antibody-Drug Conjugate Conference (World ADC) was held in London, UK. Dr. Guitao Wang,...
![](https://www.coherentbio.com/wp-content/uploads/2024/02/1-800x740.jpg)
Author By adminPosted on
On October 18, 2023, Dr. Robert Huang, Founder, Chairman, and CEO of Coherent Biopharma, unveiled the latest clinical data on the company's leading pipeline product, CBP-1008, at the 14th World ADC Conference.
![](https://www.coherentbio.com/wp-content/uploads/2023/09/FDA-800x740.png)
Author By adminPosted on
Coherent Biopharma announced today that their proprietary second-generation dual-ligand conjugate drug, CBP-1019, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) on …
![](https://www.coherentbio.com/wp-content/uploads/2023/06/6382580559359796232853352-1.png)
Author By adminPosted on
Coherent Biopharma announced that clinical data will be presented in the form of a poster at the 2023 European Society for Medical...
![](https://www.coherentbio.com/wp-content/uploads/2023/06/新闻默认图.jpg)
Author By adminPosted on
CBP-1018 is the first dual-ligand conjugate drug targeting PSMA and FRα developed on Coherent Biopharma (CBP)’s Bi-XDC technolo...